January 10, 2026ESC Heart Failure1 citationsOpen Access
View Full PaperInterplay between medical and interventional therapies in valvular heart disease and heart failure: an expert opinion paper
Key Result
An integrated approach combining medical and interventional therapies may enhance quality of life and outcomes in patients with heart failure and valvular heart disease.
Key Points
- To explore how medical and interventional therapies can work together in treating heart failure and valvular heart disease.
- Reviewed current data and clinical practices
- Examined the management strategies for valvular heart disease
- Considered the use of both medical and surgical interventions
- Integrated approaches may enhance quality of life for patients
- Synergistic effects of therapies can improve outcomes
- Percutaneous procedures could be considered more frequently, even for high-risk patients
Structured PICO
P
Population
Patients with coexisting heart failure (HF) and valvular heart disease (VHD), including secondary mitral regurgitation, aortic stenosis, aortic regurgitation, and tricuspid regurgitation
I
Intervention
Integrated approach combining guideline-directed medical therapy (GDMT) and interventional (surgical or percutaneous) therapies
C
Comparator
Traditional step-by-step approach (prioritizing GDMT and reserving interventional options for persistent symptoms or worsening HF)
This expert opinion paper advocates for an integrated, rather than sequential, approach to medical and interventional therapies in patients with coexisting heart failure and valvular heart disease.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
Abstract Heart failure (HF) and valvular heart disease (VHD) often coexist and share complex pathophysiological pathways. Traditional management strategies follow a step-by-step approach, prioritizing guideline-directed medical therapy (GDMT) and reserving interventional (surgical or percutaneous) options only in case of persistent symptoms or worsening HF after GDMT. However, greater experience with the use of percutaneous procedures, even in high-risk patients, could support a more integrated approach, which exploits the synergistic effects of medical and interventional therapies to increase the tolerability of one vs the other, thereby improving quality of life and outcomes through their synergic effects. This expert opinion paper summarizes current data and evolving practices in the management of VHD in patients with HF, including secondary mitral regurgitation, aortic stenosis, aortic regurgitation, and tricuspid regurgitation.